In Silico Studies Comparing the Adjuvant Therapies Approved for Parkinson’s disease

Abstract

One of the most common neurodegenerative disorders is Parkinson s disease. The occurrence of Parkinson s disease includes loss of dopaminergic function and loss of motor function. It is characterized by nonmotor as well as motor features. The medicine sector has been primarily focusing on developing adjunctive therapy for the treatment of Parkinson s disease in order to improve the efficacy of the drugs and to improve the quality of treatment. This study aims in silico screening of the drugs available for adjunctive therapy of Parkinson’s disease. The pharmacokinetic parameters, potential adverse effects, toxicity studies, biological activity and the structure activity relationships of the drugs were analyzed and summarized. The drugs chosen as adjunctive therapy in the treatment of Parkinson s disease have reported high chances of adverse drug events and require precautions before administration. Although, they are therapeutically effective it is necessary to investigate other available therapies and then conclude their efficacy.